| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022270289 |
| P356 | DOI | 10.1007/S11060-015-1716-2 |
| P698 | PubMed publication ID | 25577401 |
| P2093 | author name string | Shiao-Pei Weathers | |
| Mark R Gilbert | |||
| P2860 | cites work | Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab | Q38012057 |
| Oncolytic virotherapy | Q38025263 | ||
| Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance | Q38124438 | ||
| Immunobiology of human gliomas | Q38160569 | ||
| Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death | Q40082305 | ||
| Inflammatory cytokines in the brain: does the CNS shape immune responses? | Q40587473 | ||
| Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. | Q40668189 | ||
| Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway | Q44432093 | ||
| Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma | Q44980797 | ||
| Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy | Q45180266 | ||
| Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells | Q45386474 | ||
| Gene expression profiling of gliomas strongly predicts survival | Q46043661 | ||
| Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report | Q46352800 | ||
| Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination | Q46859959 | ||
| Inflammatory infiltrates and natural killer cell presence in human brain tumors | Q48111765 | ||
| Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function | Q48220006 | ||
| CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo | Q48266405 | ||
| Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-8(77)). | Q48312646 | ||
| What is immune privilege (not)? | Q48356667 | ||
| Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction. | Q55490159 | ||
| Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma | Q60922528 | ||
| Thunder and lightning: immunotherapy and oncolytic viruses collide | Q24597894 | ||
| Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma | Q24615166 | ||
| Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma | Q27005902 | ||
| Immunotherapy for brain cancer: recent progress and future promise | Q27015881 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization | Q28185520 | ||
| Adoptive immunotherapy for cancer: harnessing the T cell response | Q28262548 | ||
| Immunogenic Cell Death in Cancer Therapy | Q29620118 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 | Q29622893 | ||
| Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor | Q30442773 | ||
| The transcriptional network for mesenchymal transformation of brain tumours. | Q33572162 | ||
| Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model | Q33610214 | ||
| T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta | Q33929154 | ||
| Efficient cross-presentation depends on autophagy in tumor cells | Q34001972 | ||
| Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape | Q34136498 | ||
| Immunologically privileged sites | Q34179710 | ||
| Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma? | Q34480557 | ||
| Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma | Q34488771 | ||
| Complete regression of a previously untreated melanoma brain metastasis with ipilimumab | Q34617578 | ||
| Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma | Q34722415 | ||
| Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma | Q34787640 | ||
| Prostate cancer as a model for tumour immunotherapy | Q34856875 | ||
| Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity | Q35076737 | ||
| IDO and tolerance to tumors | Q35628246 | ||
| Structural alterations of the epidermal growth factor receptor gene in human gliomas | Q36930689 | ||
| Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial | Q37278379 | ||
| Modulation of T-cell function by gliomas | Q37543281 | ||
| Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma | Q37641262 | ||
| Response assessment challenges in clinical trials of gliomas | Q37738776 | ||
| The brain tumor microenvironment. | Q37858940 | ||
| P433 | issue | 3 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 331-337 | |
| P577 | publication date | 2015-01-11 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Current challenges in designing GBM trials for immunotherapy | |
| P478 | volume | 123 |
| Q93084804 | A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma |
| Q26773514 | Advances in the treatment of newly diagnosed glioblastoma |
| Q38603909 | An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors |
| Q88175987 | Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments |
| Q36201736 | Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis |
| Q46860353 | Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. |
| Q39381281 | Engineering challenges for brain tumor immunotherapy |
| Q57451427 | Immunotherapy in CNS cancers: the role of immune cell trafficking |
| Q37050960 | Immunotherapy in glioblastoma: emerging options in precision medicine |
| Q39312420 | MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. |
| Q52145169 | Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin |
Search more.